Glycosaminoglycan is a type of long, unbranched polysaccharide molecule. Glycosaminoglycans are major structural components of cartilage and are also found in the cornea of the eye.
In some patients who died with severe COVID-19 and respiratory failure, a jelly was formed in the lungs. Researchers have now established what the active agent in the jelly is and thanks to that, this new discovery can now be the key to new effective therapies.
Accumulation of assembled tau protein in the central nervous system is characteristic of Alzheimer's disease and several other neurodegenerative diseases, called tauopathies.
Researchers around the world are racing to find treatments to tackle the COVID-19 pandemic that has caused more than 16 million human infections globally.
An international team of researchers has conducted a study showing that differences in the human microbiome may influence the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.
A common drug, already approved by the Food and Drug Administration, may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.
Researchers at Radboud University Medical Center in the Netherlands reported an increase of heparanase activity and heparan sulfate levels in the plasma of patients with coronavirus disease (COVID-19), which was also associated with the severity of the condition – suggesting, in turn, potential treatment utility of low molecular weight heparins. The paper is currently available on the medRxiv* preprint server.
Researchers at the University of Sheffield have developed a new assay that can be used to assess the attachment of viruses to host cells and to test potential inhibitors of viral infection.
Glycosaminoglycans can inhibit cell invasion by acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other coronaviruses, which supports the utilization of such therapeutics in the fight against coronavirus disease (COVID-19) – reports a new study available on the preprint server bioRxiv.
The neurobiological pathophysiology of schizophrenia differs significantly between males and females, according to a new study.
In a study published online in Nature on June 26, research teams led by Dr. YANG Weiwei at the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences and Dr. LI Guohui from the Dalian Institute of Chemical Physics of CAS reported a new function of uridine diphosphate glucose (UDP-glucose), a metabolic intermediate in the uronic acid pathway: It impairs lung cancer metastasis by accelerating SNAI1 mRNA decay.
Using FACS-based CRISPR screening, scientists have identified three candidate genes that may facilitate the invasion of Chlamydia trachomatis into host cells.
More than 30 million Americans suffer from osteoarthritis of the knee, according to the Centers for Disease Control and Prevention.
Biomedical scientists at the University of Salford found that sugars from the common cockle were approximately as effective as some standard chemotherapy drugs at relative lower dosage.
Scientists in Dresden, Germany, have been successful in mimicking mechanisms of Alzheimer's disease in a novel, stem cell-based model system that reproduces features of human brain tissue.
Higher leisure-time physical activity (LTPA) level promotes cartilage health in postmenopausal women with mild knee osteoarthritis (OA).
The quest for a synthetic heart valve that faithfully mimics the original is a step closer to its goal with the Rice University find that a natural polymer called hyaluronan, one of the chief components of skin and connective tissue, can serve as a versatile template for growing spongiosa, the middle tissue layer in the valve's leaflets.
Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.
Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.
Halozyme Therapeutics, Inc. today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial evaluating subcutaneous (SC) delivery of daratumumab with Halozyme's proprietary ENHANZE technology in multiple myeloma.
Halozyme Therapeutics, Inc. today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a compound discovered by GlycoMimetics, Inc. and being developed by Pfizer Inc., using Halozyme's ENHANZE formulation.